Answers are grounded in this paper and cite their sources.
Amid growing concerns that some antidepressants may make some children suicidal, the U.S. Food and Drug Administration (FDA) acknowledged a possible risk in a public hearing this week. Members of its drug advisory panel urged that, pending more information, stronger warnings should be put on labels for selective serotonin reuptake inhibitors (SSRIs). There's a "signal" in the data from some clinical trials of children taking SSRIs, officials said at the hearing in the crowded ballroom of a hotel in Bethesda, Maryland. The agency put forth plans for a thorough review of research to find out what, if anything, that signal means.
No takes yet. Share an insight, caveat, or question.
Constance Holden (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: